Molecular profiling of intrahepatic and extrahepatic cholangiocarcinoma using next generation sequencing

Juan Putra; Francine B. de Abreu; Jason D. Peterson; J. Marc Pipas; Kabir Mody; Christopher I. Amos; Gregory J. Tsongalis; Arief A. Suriawinata

doi:10.1016/j.yexmp.2015.07.005

Molecular profiling of intrahepatic and extrahepatic cholangiocarcinoma using next generation sequencing

Juan Putra, Francine B. de Abreu, Jason D. Peterson, J. Marc Pipas, Kabir Mody, Christopher I. Amos, Gregory J. Tsongalis, Arief A. Suriawinata

Hematology / Oncology / Cancer Center / Breast Clinic

Research output: Contribution to journal › Article › peer-review

27 Scopus citations

Abstract

Cholangiocarcinoma is a heterogeneous malignant process, which is further classified into intrahepatic cholangiocarcinoma (ICC) and extrahepatic cholangiocarcinoma (ECC). The poor prognosis of the disease is partly due to the lack of understanding of the disease mechanism. Multiple gene alterations identified by various molecular techniques have been described recently. As a result, multiple targeted therapies for ICC and ECC are being developed. In this study, we identified and compared somatic mutations in ICC and ECC patients using next generation sequencing (NGS) (Ampliseq Cancer Hotspot Panel v2 and Ion Torrent 318v2 chips). Eleven of 16 samples passed internal quality control established for NGS testing. ICC cases (n. =. 3) showed IDH1 (33.3%) and NRAS (33.3%) mutations. Meanwhile, TP53 (75%), KRAS (50%), and BRAF (12.5%) mutations were identified in ECC cases (n. =. 8). Our study confirmed the molecular heterogeneity of ICC and ECC using NGS. This information will be important for individual patients as targeted therapies for ICC and ECC become available in the future.

Original language	English (US)
Pages (from-to)	240-244
Number of pages	5
Journal	Experimental and Molecular Pathology
Volume	99
Issue number	2
DOIs	https://doi.org/10.1016/j.yexmp.2015.07.005
State	Published - Oct 1 2015

Keywords

Extrahepatic cholangiocarcinoma
Intrahepatic cholangiocarcinoma
Next generation sequencing
Somatic mutations
Targeted therapy

ASJC Scopus subject areas

Pathology and Forensic Medicine
Molecular Biology
Clinical Biochemistry

Access to Document

10.1016/j.yexmp.2015.07.005

Fingerprint Dive into the research topics of 'Molecular profiling of intrahepatic and extrahepatic cholangiocarcinoma using next generation sequencing'. Together they form a unique fingerprint.

Cite this

Molecular profiling of intrahepatic and extrahepatic cholangiocarcinoma using next generation sequencing. / Putra, Juan; de Abreu, Francine B.; Peterson, Jason D.; Pipas, J. Marc; Mody, Kabir; Amos, Christopher I.; Tsongalis, Gregory J.; Suriawinata, Arief A.

In: Experimental and Molecular Pathology, Vol. 99, No. 2, 01.10.2015, p. 240-244.

Research output: Contribution to journal › Article › peer-review

@article{2aa1be424a284b0593238e93fd09178a,

title = "Molecular profiling of intrahepatic and extrahepatic cholangiocarcinoma using next generation sequencing",

abstract = "Cholangiocarcinoma is a heterogeneous malignant process, which is further classified into intrahepatic cholangiocarcinoma (ICC) and extrahepatic cholangiocarcinoma (ECC). The poor prognosis of the disease is partly due to the lack of understanding of the disease mechanism. Multiple gene alterations identified by various molecular techniques have been described recently. As a result, multiple targeted therapies for ICC and ECC are being developed. In this study, we identified and compared somatic mutations in ICC and ECC patients using next generation sequencing (NGS) (Ampliseq Cancer Hotspot Panel v2 and Ion Torrent 318v2 chips). Eleven of 16 samples passed internal quality control established for NGS testing. ICC cases (n. =. 3) showed IDH1 (33.3%) and NRAS (33.3%) mutations. Meanwhile, TP53 (75%), KRAS (50%), and BRAF (12.5%) mutations were identified in ECC cases (n. =. 8). Our study confirmed the molecular heterogeneity of ICC and ECC using NGS. This information will be important for individual patients as targeted therapies for ICC and ECC become available in the future.",

keywords = "Extrahepatic cholangiocarcinoma, Intrahepatic cholangiocarcinoma, Next generation sequencing, Somatic mutations, Targeted therapy",

author = "Juan Putra and {de Abreu}, {Francine B.} and Peterson, {Jason D.} and Pipas, {J. Marc} and Kabir Mody and Amos, {Christopher I.} and Tsongalis, {Gregory J.} and Suriawinata, {Arief A.}",

year = "2015",

month = oct,

day = "1",

doi = "10.1016/j.yexmp.2015.07.005",

language = "English (US)",

volume = "99",

pages = "240--244",

journal = "Experimental and Molecular Pathology",

issn = "0014-4800",

publisher = "Academic Press Inc.",

number = "2",

}

TY - JOUR

T1 - Molecular profiling of intrahepatic and extrahepatic cholangiocarcinoma using next generation sequencing

AU - Putra, Juan

AU - de Abreu, Francine B.

AU - Peterson, Jason D.

AU - Pipas, J. Marc

AU - Mody, Kabir

AU - Amos, Christopher I.

AU - Tsongalis, Gregory J.

AU - Suriawinata, Arief A.

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Cholangiocarcinoma is a heterogeneous malignant process, which is further classified into intrahepatic cholangiocarcinoma (ICC) and extrahepatic cholangiocarcinoma (ECC). The poor prognosis of the disease is partly due to the lack of understanding of the disease mechanism. Multiple gene alterations identified by various molecular techniques have been described recently. As a result, multiple targeted therapies for ICC and ECC are being developed. In this study, we identified and compared somatic mutations in ICC and ECC patients using next generation sequencing (NGS) (Ampliseq Cancer Hotspot Panel v2 and Ion Torrent 318v2 chips). Eleven of 16 samples passed internal quality control established for NGS testing. ICC cases (n. =. 3) showed IDH1 (33.3%) and NRAS (33.3%) mutations. Meanwhile, TP53 (75%), KRAS (50%), and BRAF (12.5%) mutations were identified in ECC cases (n. =. 8). Our study confirmed the molecular heterogeneity of ICC and ECC using NGS. This information will be important for individual patients as targeted therapies for ICC and ECC become available in the future.

AB - Cholangiocarcinoma is a heterogeneous malignant process, which is further classified into intrahepatic cholangiocarcinoma (ICC) and extrahepatic cholangiocarcinoma (ECC). The poor prognosis of the disease is partly due to the lack of understanding of the disease mechanism. Multiple gene alterations identified by various molecular techniques have been described recently. As a result, multiple targeted therapies for ICC and ECC are being developed. In this study, we identified and compared somatic mutations in ICC and ECC patients using next generation sequencing (NGS) (Ampliseq Cancer Hotspot Panel v2 and Ion Torrent 318v2 chips). Eleven of 16 samples passed internal quality control established for NGS testing. ICC cases (n. =. 3) showed IDH1 (33.3%) and NRAS (33.3%) mutations. Meanwhile, TP53 (75%), KRAS (50%), and BRAF (12.5%) mutations were identified in ECC cases (n. =. 8). Our study confirmed the molecular heterogeneity of ICC and ECC using NGS. This information will be important for individual patients as targeted therapies for ICC and ECC become available in the future.

KW - Extrahepatic cholangiocarcinoma

KW - Intrahepatic cholangiocarcinoma

KW - Next generation sequencing

KW - Somatic mutations

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84938079607&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938079607&partnerID=8YFLogxK

U2 - 10.1016/j.yexmp.2015.07.005

DO - 10.1016/j.yexmp.2015.07.005

M3 - Article

C2 - 26189129

AN - SCOPUS:84938079607

VL - 99

SP - 240

EP - 244

JO - Experimental and Molecular Pathology

JF - Experimental and Molecular Pathology

SN - 0014-4800

IS - 2

ER -